Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic and keeping the price target at $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Caufield has given his Buy rating due to a combination of factors, primarily centered around the promising data from Immunic’s lead candidate, Vidofludimus calcium, in treating multiple sclerosis (MS). The recent long-term data from the Phase 2 EMPhASIS trial showed significant efficacy in patients with relapsing-remitting MS, with a high percentage of patients remaining free from confirmed disability worsening over extended periods. This efficacy, combined with the drug’s favorable safety and tolerability profile over 5.5 years, supports its potential for improved disease management.
Furthermore, the dual mechanism of Vidofludimus calcium, which includes neuroprotection and anti-inflammatory effects, enhances its role as a selective immune modulator. The positive outcomes from the Phase 2 CALLIPER trial in progressive MS patients, such as reduced risk of disability worsening and neuroprotective benefits, further bolster confidence in its therapeutic potential. With global enrollment completed for the pivotal Phase 3 trials and results expected by 2026, there is a strong opportunity for investor engagement, reinforcing the Buy rating and the $10 price target.
In another report released on August 7, Leerink Partners also reiterated a Buy rating on the stock with a $4.00 price target.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMUX in relation to earlier this year.